Histamine-succinyl-glycine hapten-binding paratope (HSG-binding paratope)

The Histamine-succinyl-glycine (HSG) hapten-binding paratope is a specialized molecular recognition site engineered into bispecific antibodies to facilitate pre-targeting strategies in oncology. This paratope, often derived from the high-affinity 679 antibody, is designed to bind specifically to the small HSG hapten with nanomolar affinity (Sharkey et al., 2003, PubMed: 12615916). In a typical therapeutic application, a bispecific antibody containing this paratope is administered first to localize to tumor-associated antigens, such as CEA or Trop-2, and allowed to clear from the bloodstream (Goldenberg et al., 2012, PubMed: 22442314). Subsequently, a small HSG-labeled peptide carrying a therapeutic radioisotope or imaging agent is injected, which rapidly binds to the paratope at the tumor site while excess peptide is quickly excreted through the kidneys (Schoffelen et al., 2013, PubMed: 23303603). This decoupled approach minimizes the exposure of healthy tissues to radiation compared to conventional radioimmunotherapy, where the isotope is directly attached to a long-circulating full-length antibody. The HSG-binding paratope thus acts as a synthetic receptor, enabling high-contrast imaging and potent localized therapy for various solid tumors (van Rij et al., 2014, PubMed: 24434295).

Other names

Anti-HSG binding site679 antibody paratopeHSG-binding armHistamine-succinyl-glycine binding domainm679 paratopeh679 paratope

The paratope functions as a high-affinity docking site for HSG-labeled payloads in a multi-step pre-targeting system. A bispecific antibody first binds a tumor antigen; once cleared from circulation, an HSG-labeled peptide is administered, which binds the paratope to deliver radiation or drugs directly to the tumor site.